PatternsRadar
Sign in

ONESOURCEOnesource Specialty Pharma Limited

NSE
1,609.30INR+6.40 (+0.40%)Close · 20 Nov 2026
27 Oct 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹18,455 CrMarket cap
—P/E (TTM)
57.7%Delivery

Filings & corporate actions

9 results filed
CSV
Next results · Q3 FY27
Expected 23 Jan 2027 – 12 Feb 2027
Estimate: filed 23–43 days after quarter end, last 7 times
2026
  • 27 OctresultsResults · Q2 FY27 · consolidated and standalone+13.8%NSE
  • 21 OctshareholdingShareholding · 30 Sept 2026-0.7%NSE
  • 24 JulresultsResults · Q1 FY27 · consolidated and standalone+2.1%NSE
  • 21 JulshareholdingShareholding · 30 Jun 2026-2.5%NSE
  • 13 MayresultsResults · Q4 FY26 · consolidated and standalone+1.7%NSE
  • 20 AprshareholdingShareholding · 31 Mar 2026+0.4%NSE
  • 23 JanresultsResults · Q3 FY26 · consolidated and standalone-19.6%NSE
  • 20 JanshareholdingShareholding · 31 Dec 2025-2.5%NSE

Reaction to results · all yearsrose on day 0 in 5 of 9 CSV

QuarterFiledDay 0+5D+20DRel vol
Q2 FY2727 Oct 2026+13.8%+12.3%—36.1×
Q1 FY2724 Jul 2026+2.1%-5.6%-7.4%2.3×
Q4 FY2613 May 2026+1.7%+4.0%-9.9%0.3×
Q3 FY2623 Jan 2026-19.6%-18.0%-7.6%19.0×
Q2 FY2611 Nov 2025+0.3%-2.8%-3.4%0.7×
Q1 FY264 Aug 2025-1.2%-0.9%-2.0%1.9×
Q4 FY255 May 2025-1.9%-0.6%+12.8%2.9×
Q2 FY2510 Feb 2025-2.2%-11.9%-2.1%—
Q3 FY2529 Jan 2025+0.9%-3.5%-20.3%—
Average-0.7%-3.0%-5.0%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q2 FY27

Revenue YoY+37.4%
Profit YoY+448.2%
Interest cost YoY-10.3%
Revenue QoQ+15.0%
Profit QoQ+130.0%
CAGR2Y3Y4Y5Y6Y7Y
Revenue——————
Profit——————

Key data

Open1,585.00
Day range1,574.30 – 1,621.90
52-week range1,057.00 – 1,917.80
From 52w high-16.1%
RSI (14)58.0
ATR (14)56.08
Volume1.79L
Avg volume (20D)8.95L
Rel volume0.20×
Volatility (1Y)45.2%
Turnover₹28.6Cr
Traded value (NSE)₹28.6Cr
VWAP1,599.42
SMA 50 / 2001,539.60 / 1,556.02
Price band20%

Delivery percentage

Latest · 20 Nov 202657.7%
20-day avg49.4%
1-year avg49.0%
Percentile (own history)63rd
Range16.2–100.0%
Sessions452

Over the last 20 sessions ONESOURCE settled 49.4% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 49.0%. The latest session ranks higher than 63% of the 452 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Dividends, deals & holders

Dividend yield0.00%
Dividend, trailing 12M₹0.00
Paid every year for0 yr
Shareholders79.8K · +2.4% QoQ
Net bulk deals, 30D0.00%
Block deals, 30D₹0
Last bulk buy213 days ago

Performance returns

1D1W1M3M6M1Y
Price+0.40%-0.05%+16.80%+4.87%-13.56%-7.08%

Valuation

Market cap₹18,455 Cr
Market cap (NSE)₹18,454 Cr
Free-float cap₹12,831 Cr
P/E (TTM)—
P/E (NSE)—
EPS (TTM)-0.14
P/B3.1
Net margin (TTM)-0.1%
Other income / PBT—
ROE-0.0%
Debt / equity0.25
Shares outstanding11.47Cr
Listed24 Jan 2025

Ownership

Promoter30.47%
Promoter Δ QoQ-0.01 pp
Public69.53%
FII19.46%
DII24.21%
Pledged38.79%

Quarterly results · consolidated

Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue (₹ Cr)290.3428.2449.0516.2
YoY chg-26.0%+0.5%+37.2%+37.4%
Net profit (₹ Cr)(88.7)4.625.057.5
YoY chg—-95.3%—+448.2%
Net margin-30.6%1.1%5.6%11.1%
EPS-7.740.402.185.01

Shareholding over time

By quarter

30 Sept 2026 · promoter 30.47% · public 69.53%
1 Dec 2024: promoter 37.77%31 Dec 2024: promoter 37.77%31 Mar 2025: promoter 34.25%30 Jun 2025: promoter 29.79%30 Sept 2025: promoter 29.77%31 Dec 2025: promoter 29.93%31 Mar 2026: promoter 30.48%30 Jun 2026: promoter 30.48%30 Sept 2026: promoter 30.47%
2024-122026-09
  • Promoter
  • Public and others
Promoter
30.47%
Public
69.53%
Promoter change
-0.01 pp
Filed
21 Oct 2026
FII
19.46%
DII
24.21%
Promoter pledged
38.79%

Who the public is

Mutual funds
13.76%

+0.78 pp QoQ

Insurance
4.12%

+1.26 pp QoQ

FPI
19.45%

+0.26 pp QoQ

Retail ≤ ₹2L
9.95%

+0.64 pp QoQ

HNI > ₹2L
1.28%

-0.70 pp QoQ

NRI
0.87%

+0.05 pp QoQ

Bodies corporate
7.33%

+0.13 pp QoQ

Shareholders
79,770

+2.4% QoQ

Major holders

As of 30 Sept 2026
HolderTypeHolding
TENSHI PHARMACEUTICALS PRIVATE LIMITEDPromoter · Corporate18.39%
KARUNA BUSINESS SOLUTIONS LLPPromoter · Corporate7.06%
MOTILAL OSWAL MUTUAL FUNDMutual fund7.02%
AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITEDCorporate4.95%
SBI LIFE INSURANCE CO. LTDInsurance2.89%
PRONOMZ VENTURES LLPPromoter · Corporate2.41%
ROUTE ONE OFFSHORE MASTER FUND L.P.FPI2.32%
ROUTE ONE FUND I, L.P.FPI2.07%
THINK INVESTMENTS PCCCorporate1.79%
FIDELITY SECURITIES FUND: FIDELITY BLUE CHIP GROWTH FUNDFPI1.76%

Every promoter-group member, and each public holder above 1%, as filed.

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.

Insider trades

Insiders net, 30d
₹0
Insiders net, 90d
₹0
Promoters net, 90d
₹0
Insider buyers, 90d
0
Last promoter buy
9 months ago
Disclosures on record
16
15 open-market of the newest 16
By year
BroadcastPersonSideSharesValuePriceHolding before → afterStakeRegulation
6 Feb 2026TENSHI PHARMACEUTICALS PRIVATE LIMITEDPromoterBuy85.0K~₹10.3Cr1,213.702.10Cr → 2.11Cr18.40%+0.07 pp7(2)told 4 Feb 2026
6 Feb 2026TENSHI PHARMACEUTICALS PRIVATE LIMITEDPromoterBuy2.05L₹23.9Cr1,164.762.08Cr → 2.10Cr18.33%+0.18 pp7(2)told 4 Feb 2026
6 Feb 2026PRONOMZ VENTURES LLPPromoterBuy45.0K₹5.1Cr1,132.2327.16L → 27.61L2.41%+0.04 pp7(2)told 4 Feb 2026
6 Feb 2026PRONOMZ VENTURES LLPPromoterBuy33.9K₹4.0Cr1,194.0226.82L → 27.16L2.37%+0.03 pp7(2)told 2 Feb 2026
6 Feb 2026Tenshi Pharmaceuticals Private LimitedPromoterBuy75.0K₹8.7Cr1,161.782.07Cr → 2.08Cr18.15%+0.07 pp7(2)told 2 Feb 2026
6 Feb 2026Tenshi Pharmaceuticals Private LimitedPromoterBuy2.00L~₹23.1Cr1,155.102.05Cr → 2.07Cr18.09%+0.17 pp7(2)told 28 Jan 2026
10 Feb 2025Sajitha PillaiPromoterSell5.0K₹77.4L1,547.8440.0K → 35.0K0.03%-0.00 pp7(2)told 7 Feb 2025
6 Feb 2025Sajitha PillaiPromoterSell7.5K₹1.1Cr1,532.0647.5K → 40.0K0.03%-0.01 pp7(2)told 6 Feb 2025
6 Feb 2025Neeraj SharmaDirectorSell20.0K₹3.0Cr1,487.151.56L → 1.36L0.12%-0.02 pp7(2)told 3 Feb 2025
6 Feb 2025Vineetha Mohankumar PillaiPromoterSell47.5K₹7.4Cr1,565.3895.0K → 47.5K0.04%-0.04 pp7(2)told 3 Feb 2025
6 Feb 2025Padmakumar Karunakaran PillaiPromoterSell50.0K₹7.8Cr1,558.7393.2K → 43.2K0.04%-0.05 pp7(2)told 3 Feb 2025
6 Feb 2025Hemalatha PillaiPromoterSell18.0K₹2.6Cr1,453.0721.4K → 3.4K0.00%0.00 pp7(2)told 4 Feb 2025
6 Feb 2025Hemalatha PillaiPromoterSell12.0K₹1.9Cr1,579.6233.4K → 21.4K0.02%-0.01 pp7(2)told 3 Feb 2025
6 Feb 2025Tenshi Pharmaceuticals Private LimitedPromoterSell33.01L₹505.6Cr1,531.742.38Cr → 2.05Cr17.94%-2.89 pp7(2)told 3 Feb 2025
6 Feb 2025Pronomz Ventures LLPPromoterSell5.83L₹90.0Cr1,545.0083.67L → 77.85L6.80%-0.51 pp7(2)told 3 Feb 2025

SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.

How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session

Bulk & block deals · 21 Apr 2026

CSV
12 of 13 deals
By year
DateDealClientQuantityPriceValue
21 Apr 2026Buy · bulkFIDELITY SECURITIES FUND: FIDELITY BLUE CHIP GROWTH FUND20.18L1,530.00₹308.7Cr
21 Apr 2026Sell · bulkNOVA GLOBAL OPPORTUNITIES FUND PCC - TOUCHSTONE10.58L1,530.00₹161.9Cr
21 Apr 2026Sell · bulkAUTHUM INVESTMENT & INFRASTRUCTURE LIMITED9.50L1,530.09₹145.4Cr
21 Apr 2026Buy · bulkAUTHUM INVESTMENT & INFRASTRUCTURE LIMITED1.73L1,556.69₹26.9Cr
17 Nov 2025Sell · blockAMANSA HOLDING PRIVATE LTD.2.00L1,735.00₹34.7Cr
17 Nov 2025Buy · blockKARUNA BUSINESS SOLUTIONS LLP2.00L1,735.00₹34.7Cr
31 Jan 2025Sell · bulkMEDELLA HOLDINGS PTE. LTD.19.42L1,552.90₹301.5Cr
31 Jan 2025Sell · bulkMEDELLA HOLDINGS PTE. LTD.19.42L1,548.54₹300.7Cr
31 Jan 2025Sell · bulkTENSHI PHARMACEUTICALS PRIVATE LIMITED19.42L1,545.03₹300.0Cr
31 Jan 2025Sell · bulkTENSHI PHARMACEUTICALS PRIVATE LIMITED13.59L1,545.00₹210.0Cr
31 Jan 2025Buy · bulkCPT RESEARCH & MGMT CO T/A CPT WORLD INVESTORS11.40L1,545.00₹176.2Cr
31 Jan 2025Buy · bulkMOTILAL OSWAL MUTUAL FUND A/C MOTILAL OSWAL LARGE AND MIDCAP FUND10.55L1,545.00₹163.0Cr

A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.

Every stock on this session →

Takeover-code disclosures

Loading…

Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.

Every stock on this session →

Short selling, lending & margin

Loading…

Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.

Exchange surveillance

20 Nov 2026
  • Zero EPS (4 quarters) · since 14 May 2026 — Zero EPS over the last four quarters.

Price band: 20% · not in the F&O ban.

From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.

Every stock on this session →

Financials · quarterly statement

₹ crore, as filed
By year
 Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27Q2 FY27
Revenue from operations68.0392.6426.0327.3375.8290.3428.2449.0516.2
Other income0.65.42.95.33.04.62.13.81.0
Total income68.6398.0428.8332.5378.8295.0430.3452.8517.2
Total expenses107.6363.9345.3334.1373.1380.9430.6428.2462.6
└ Finance costs20.745.833.427.534.038.222.530.834.6
└ Depreciation19.168.868.567.869.869.671.871.775.1
Profit before tax(39.1)(66.5)83.5(4.4)5.7(93.0)(0.3)20.352.9
Tax expense0.02.3(15.4)(4.2)(4.7)(4.3)(4.9)(4.7)(4.6)
Net profit(39.3)(68.8)98.2(0.2)10.5(88.7)4.625.057.5
EPS-18.82-6.318.61-0.020.92-7.740.402.185.01
Net margin-57.85%-17.54%23.05%-0.06%2.79%-30.55%1.07%5.57%11.14%
PBT margin-57.49%-16.94%19.60%-1.34%1.53%-32.04%-0.07%4.52%10.24%
Tax rate——-18.43%—-82.63%——-23.17%-8.74%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 27 Oct 2026.

Balance sheet & cash flow · half-yearly

₹ crore, as filed
By year

Balance sheet

 H1 FY25FY25H1 FY26FY26H1 FY27
Total assets1,282.87,550.28,013.38,210.08,586.1
Current assets158.11,086.21,354.71,425.91,697.5
└ Cash & equivalents8.7156.5103.535.714.2
└ Other bank balances24.6144.459.261.918.8
└ Current investments7.28.94.15.55.6
└ Trade receivables63.4416.6664.3690.21,032.9
└ Inventories13.8158.1325.3439.0445.9
Total equity404.95,880.65,904.55,831.35,920.9
└ Attributable to owners404.95,880.65,904.55,831.35,920.9
└ Non-controlling interest—0.00.0—0.0
└ Share capital4.211.411.511.511.5
Borrowings603.6771.61,066.01,276.31,483.6
└ Current150.2552.3673.0712.6899.4
└ Non-current453.5219.3393.0563.7584.2
Trade payables53.7175.5284.0374.6535.5
Current liabilities413.81,113.61,331.01,442.01,663.6
Total liabilities877.91,669.72,108.82,378.72,665.2
Net debt563.2461.8899.21,173.31,445.1
Debt / equity1.490.130.180.220.25
Current ratio0.380.981.020.991.02

Cash flow, year to date

 H1 FY25FY25H1 FY26FY26H1 FY27
Operating cash flow(80.8)(21.5)(39.9)8.5(19.2)
└ Capex(30.0)0.0(328.7)(569.1)(171.2)
Free cash flow(110.8)(21.5)(368.6)(560.5)(190.5)
Investing cash flow0.3(201.1)(250.6)(495.0)(127.7)
Financing cash flow85.41,987.2231.3359.4125.5
└ Dividends paid0.00.00.00.00.0
└ Buybacks0.00.00.00.00.0
Net change in cash4.91,764.6(59.2)(127.0)(21.4)

From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.

Announcements & board meetings

Loading…

As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.

Every stock on this session →

ONESOURCE at a glance

  • ONESOURCE closed at ₹1,609.3 on 20 Nov 2026, +0.40% on the day, -7.1% over one year, 16.1% below its 52-week high of ₹1,917.8.
  • Delivery was 57.7% of traded quantity on 20 Nov 2026, the 63rd percentile of its own 452 sessions with a reading (20-session average 49.4%, 1-year average 49.0%).
  • Market capitalisation is ₹18,455 crore, with no positive trailing earnings for a P/E (trailing EPS ₹-0.14).
  • Q2 FY27 results (consolidated, filed 27 Oct 2026): revenue ₹516 crore (+37.4% year on year), net profit ₹57 crore (+448.2%); the price moved +13.8% on the first session after.
  • Promoters held 30.47% at 30 Sept 2026, down 0.01 percentage points on the previous filing, with 38.79% of promoter shares pledged.
  • Q3 FY27 results are expected between 23 Jan 2027 and 12 Feb 2027, going by past filing dates — an estimate, not an announcement.

About

Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE013P01021
SeriesEQ
Listed24 Jan 2025
NSE market cap · 17 Nov 2026₹18,128 Cr
Free-float market cap (NSE)₹12,410 Cr
Shares outstanding (NSE)11.47Cr
History from24 Jan 2025
Sessions452
Turnover rank#217

Sector history

  1. to 16 Aug 2026Index industry · Healthcare
  2. from 16 Aug 2026Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

NSE’s own classification, by the snapshot it changed on.

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.